10 completed, 2 terminated. 7 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 5, Terminated 2 |
| Phase 2 | 5 | Completed 5 |
Follow ispronicline: new trials by email Literature Review of ispronicline trials Research Report on ispronicline
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD) Donepezil, AZD3480 - Alzheimer's Disease | Phase 2 | Completed | Targacept Inc. | 386 | 2011-10-01 | 2015-06-03 |
| Pharmacokinetic Interaction Between AZD3480 and Donepezil AZD3480, Donepezil - Alzheimer's Disease | Phase 1 | Terminated | AstraZeneca | 33 | 2008-12-01 | 2014-08-15 |
| Study of Uptake, Break Down and Elimination of an Investigational Drug in Healthy Volunteers AZD3480 - Alzheimer's Disease | Phase 1 | Terminated | AstraZeneca | 9 | 2008-10-01 | 2010-11-18 |
| An Exploratory Trial of AZD3480 (TC-1734) for the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Placebo, AZD3480 - ADHD | Phase 2 | Completed | AstraZeneca | 24 | 2008-05-01 | 2009-10-30 |
| Drug Interaction Study Between AZD3480 and Aripiprazole in Healthy Subjects AZD3480, Placebo, Aripiprazole - Alzheimer's Disease | Phase 1 | Completed | AstraZeneca | 52 | 2008-03-01 | 2009-07-02 |
| Positron Emission Tomography Study Using 2-[18F]-F-A85380 to Determine α4β2 Neuronal Nicotinic Receptor Occupancy of AZD3480 After Oral Administration to Healthy Male Subjects AZD3480, 2-[18F]-F-A85380 - Healthy | Phase 1 | Completed | AstraZeneca | 9 | 2008-01-01 | 2010-12-10 |
| Investigate the Effect on the QT/QTc Interval of Repeated and Escalating Doses of AZD3480 During 6 Days AZD3480, Moxifloxacin, PLACEBO - Healthy | Phase 1 | Completed | AstraZeneca | 75 | 2008-01-01 | 2008-09-25 |
| Drug Interaction Study Between AZD3480 and Cytochrome P450 AZD3480, Placebo, Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin) - Metabolism, Alzheimer's Disease | Phase 1 | Completed | AstraZeneca | 18 | 2007-11-01 | 2008-11-26 |
| Drug Interaction Study Between AZD3480 and Warfarin AZD3480, Placebo, Warfarin - Alzheimer's Disease | Phase 1 | Completed | AstraZeneca | 26 | 2007-09-01 | 2009-07-02 |
| Proof of Concept Study of Cognitive Improvement in Patients With Schizophrenia AZD3480 - Schizophrenia | Phase 2 | Completed | AstraZeneca | 400 | 2007-08-01 | 2008-11-25 |
| Proof of Concept Study of Cognitive Improvement in Patients With Alzheimer's Disease AZD3480, Donepezil - Alzheimer Disease | Phase 2 | Completed | AstraZeneca | 659 | 2007-07-01 | 2014-07-23 |
| A Safety and Efficacy Study of Ispronicline (TC-1734-112) in Subjects With Age Associated Memory Impairment (AAMI) ispronicline (nicotinic acetylcholine receptor agonist) - Age-Related Memory Disorders | Phase 2 | Completed | Targacept Inc. | 174 | 2005-01-01 | 2008-07-18 |
Alzheimer Disease (7) · Dementia (2) · Attention Deficit Disorder with Hyperactivity (1) · Cognition Disorders (1) · Memory Disorders (1) · Schizophrenia (1)
AstraZeneca (10) · Targacept Inc. (2)
Sweden (4) · United States (4) · United Kingdom (3) · Canada (2) · Czechia (2) · Romania (2) · Austria (1) · Belgium (1) · Bulgaria (1) · Germany (1) · Russia (1) · Slovakia (1) · Spain (1) · Ukraine (1)
Cyril Clarke, MD (2) · Bo Fransson, MD (1) · Ctril Clarke, MD (1) · Larry Rodichok, MD (1) · Lennart Jeppsson (1) · Pierre Tariot, MD (1) · Simon Constable (1) · Tim Mant, Prof (1)